This site is intended for healthcare professionals only
LoginRegister
Boehringer Ingelheim Jascayd receives regulatory approval for progressive pulmonary fibrosis in ChinaBoehringer Ingelheim, 3T Biosciences enter into second partnership for cancer immunotherapies
NPPA Fixes Retail Prices for 28 Drug Formulations Including Dapagliflozin, Telmisartan, Amoxycillin, DetailsNPPA fixes Retail Prices of 19 Formulations, Details
Shilpa Medicare Enters US Transdermal Market, Files First ANDA for Rotigotine PatchSubmit PK-PD data of 3 cohorts for 7 days: CDSCO Panel Tells Shilpa Medicare on Ondansetron ER Inj...
India orders new drug-making standards after overseas deathsIndia orders new drug-making standards after overseas deaths
Eli Lilly joins trillion-dollar club, fueled by weight loss drug demand boomLilly launches end to end digital healthcare experience through LillyDirect
Merck gets USFDA Priority Review for application for Keytruda plus standard of care as Perioperative treatment for Resectable Locally Advanced Head, Neck Squamous Cell CarcinomaMerck announces Phase 3 trial initiations for 4 investigational candidates from its hematology,...
Import Nod on Hold Over False Positives, Tissue Detection: CDSCO Panel Seeks More Data on Medtronics PTeye DeviceMedtronic gets CE Mark for next generation Micra leadless pacing systems
AstraZeneca to Invest USD 15 Billion in China by 2030AstraZeneca Gets CDSCO Panel Nod to Study anti-cancer drug Dato-DXd and Durvalumab
GSK, Pfizer resolve patent lawsuit over RSV vaccinesBotox rival Revance loses bid to dismiss Allergan trade secrets lawsuit
Merck gets USFDA Priority Review for application for Keytruda plus standard of care as Perioperative treatment for Resectable Locally Advanced Head, Neck Squamous Cell CarcinomaMerck seeks GLP-1 drugs with benefits beyond weight loss, says CEO
Dr Reddys Labs inks pact with Henlius for commercialization of multiple myeloma injection HLX15 in US, EuropeDr Reddy's Labs acquires entire MenoLabs supplements portfolio
Revenue of 25 leading domestic pharma cos expected to grow 9-11 percent in current fiscal year: ICRARevenue of 25 leading domestic pharma cos expected to grow 9-11 percent in current fiscal year: ICRA
X